State of the Art 2: Targeting the Non-T Cell Microenvironment
Session Details
Moderator
Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
Presentation numberSA2-01
Fibroblast and immunosuppression in breast cancer
Fatima Mechta-Grigoriou, Institut Curie, Paris, France
F. Mechta-Grigoriou; Institut Curie, Paris, FRANCE.
Although heterogeneity of FAP+ Cancer-Associated Fibroblasts (CAF) has been described in breast cancer, their plasticity and spatial distribution remain poorly understood. Here, we analyze trajectory inference, deconvolute spatial transcriptomics at single-cell level and perform functional assays to generate a high-resolution integrated map of breast cancer (BC), with a focus on inflammatory and myofibroblastic (iCAF/myCAF) FAP+ CAF clusters. We identify 10 spatially-organized FAP+ CAF-related cellular niches, called EcoCellTypes, which are differentially localized within tumors. Consistent with their spatial organization, cancer cells drive the transition of detoxification-associated iCAF (Detox-iCAF) towards immunosuppressive extracellular matrix (ECM)-producing myCAF (ECM-myCAF) via a DPP4- and YAP-dependent mechanism. In turn, ECM-myCAF polarize TREM2+ macrophages, regulatory NK and T cells to induce immunosuppressive EcoCellTypes, while Detox-iCAF are associated with FOLR2+ macrophages in an immuno-protective EcoCellType. FAP+ CAF subpopulations accumulate differently according to the invasive BC status and predict invasive recurrence of ductal carcinoma in situ (DCIS), which could help in identifying low-risk DCIS patients eligible for therapeutic de-escalation.
Presentation numberSA2-02
Role of macrophage reprograming in Breast Cancer outcomes
Kelly Kersten, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
Presentation numberSA2-03
Targeting non T-cells in the clinic
George Plitas, Memorial Sloan Kettering Cancer Center, New York, NY
Advocate
Cheryl Jernigan, PIVOT, University of Kansas Cancer Center, Kansas City, KS